Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T.
Branford S, et al. Among authors: grigg a.
Blood. 2004 Nov 1;104(9):2926-32. doi: 10.1182/blood-2004-03-1134. Epub 2004 Jul 15.
Blood. 2004.
PMID: 15256429
Free article.